Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention

While neurotransmitter dysfunction represents a key component in mental illnesses, there is now a wide agreement for a central pathophysiological hub that includes hormones, neuroinflammation, redox mechanisms as well as oxidative stress. With respect to oxidation-reduction (redox) mechanisms, precl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacology & therapeutics (Oxford) 2020-06, Vol.210, p.107520-107520, Article 107520
Hauptverfasser: Rossetti, Andrea Carlo, Paladini, Maria Serena, Riva, Marco Andrea, Molteni, Raffaella
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 107520
container_issue
container_start_page 107520
container_title Pharmacology & therapeutics (Oxford)
container_volume 210
creator Rossetti, Andrea Carlo
Paladini, Maria Serena
Riva, Marco Andrea
Molteni, Raffaella
description While neurotransmitter dysfunction represents a key component in mental illnesses, there is now a wide agreement for a central pathophysiological hub that includes hormones, neuroinflammation, redox mechanisms as well as oxidative stress. With respect to oxidation-reduction (redox) mechanisms, preclinical and clinical evidence suggests that an imbalance in the pro/anti-oxidative homeostasis toward the increased production of substances with oxidizing potential may contribute to the etiology and manifestation of different psychiatric disorders. The substantial and continous demand for energy renders the brain highly susceptible to disturbances in its energy supply, especially following exposure to stressful events, which may lead to overproduction of reactive oxygen and nitrogen species under conditions of perturbed antioxidant defenses. This will eventually induce different molecular alterations, including extensive protein and lipid peroxidation, increased blood-brain barrier permeability and neuroinflammation, which may contribute to the changes in brain function and morphology observed in mental illnesses. This view may also reconcile different key concepts for psychiatric disorders, such as the neurodevelopmental origin of these diseases, as well as the vulnerability of selective cellular populations that are critical for specific functional abnormalities. The possibility to pharmacologically modulate the redox system is receiving increasing interest as a novel therapeutic strategy to counteract the detrimental effects of the unbalance in brain oxidative mechanisms. This review will describe the main mechanisms and mediators of the redox system and will examine the alterations of oxidative stress found in animal models of psychiatric disorders as well as in patients suffering from mental illnesses, such as schizophrenia and major depressive disorder. In addition, it will discuss studies that examined the effects of psychotropic drugs, including antipsychotics and antidepressants, on the oxidative balance as well as studies that investigated the effectiveness of a direct modulation of oxidative mechanisms in counteracting the behavioral and functional alterations associated with psychiatric disorders, which supports the promising role of the redox system as a novel therapeutic target for the improved treatment of brain disorders.
doi_str_mv 10.1016/j.pharmthera.2020.107520
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2377340050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163725820300486</els_id><sourcerecordid>2377340050</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-97033cc9a691f2e14e37699b17c24f3effc76fe978d630ea16dde9622cdf3c3c3</originalsourceid><addsrcrecordid>eNqFkE1vGyEQhlHUKHbT_oWKYy_r8rEGb2-u1bSRLOWSSLkhMgxZrN3FBWw1_z67cdocIw6D0PPODA8hlLMFZ1x92y32rU19aTHZhWBietZLwc7InK90U43M_QcyH4ustFiuZuRjzjvGWF0zcUFmUnC15FLNSXvzNzhbQhyqhO4A0432CK0dQu4zDQPd5ydogy0pAHUhx-Qw5e90TYd4xI4Wmx6xUB8TfVnKQuziYwDbjeGC6YjD1PQTOfe2y_j5tV6Su6uft5vf1fbm1_Vmva1A6rpUjWZSAjRWNdwL5DVKrZrmgWsQtZfoPWjlsdErpyRDy5Vz2CghwHkJ47kkX0999yn-OWAupg8ZsOvsgPGQjZBay5qxJRvR1QmFFHNO6M0-hd6mJ8OZmTybnXnzbCbP5uR5jH55nXJ46NH9D_4TOwI_TgCOfz0GTCZDwAHQhYRQjIvh_SnPpt6Wng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2377340050</pqid></control><display><type>article</type><title>Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rossetti, Andrea Carlo ; Paladini, Maria Serena ; Riva, Marco Andrea ; Molteni, Raffaella</creator><creatorcontrib>Rossetti, Andrea Carlo ; Paladini, Maria Serena ; Riva, Marco Andrea ; Molteni, Raffaella</creatorcontrib><description>While neurotransmitter dysfunction represents a key component in mental illnesses, there is now a wide agreement for a central pathophysiological hub that includes hormones, neuroinflammation, redox mechanisms as well as oxidative stress. With respect to oxidation-reduction (redox) mechanisms, preclinical and clinical evidence suggests that an imbalance in the pro/anti-oxidative homeostasis toward the increased production of substances with oxidizing potential may contribute to the etiology and manifestation of different psychiatric disorders. The substantial and continous demand for energy renders the brain highly susceptible to disturbances in its energy supply, especially following exposure to stressful events, which may lead to overproduction of reactive oxygen and nitrogen species under conditions of perturbed antioxidant defenses. This will eventually induce different molecular alterations, including extensive protein and lipid peroxidation, increased blood-brain barrier permeability and neuroinflammation, which may contribute to the changes in brain function and morphology observed in mental illnesses. This view may also reconcile different key concepts for psychiatric disorders, such as the neurodevelopmental origin of these diseases, as well as the vulnerability of selective cellular populations that are critical for specific functional abnormalities. The possibility to pharmacologically modulate the redox system is receiving increasing interest as a novel therapeutic strategy to counteract the detrimental effects of the unbalance in brain oxidative mechanisms. This review will describe the main mechanisms and mediators of the redox system and will examine the alterations of oxidative stress found in animal models of psychiatric disorders as well as in patients suffering from mental illnesses, such as schizophrenia and major depressive disorder. In addition, it will discuss studies that examined the effects of psychotropic drugs, including antipsychotics and antidepressants, on the oxidative balance as well as studies that investigated the effectiveness of a direct modulation of oxidative mechanisms in counteracting the behavioral and functional alterations associated with psychiatric disorders, which supports the promising role of the redox system as a novel therapeutic target for the improved treatment of brain disorders.</description><identifier>ISSN: 0163-7258</identifier><identifier>EISSN: 1879-016X</identifier><identifier>DOI: 10.1016/j.pharmthera.2020.107520</identifier><identifier>PMID: 32165136</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Animal models ; Animals ; Antidepressants ; Antioxidants - therapeutic use ; Antipsychotics ; Central Nervous System - drug effects ; Central Nervous System - metabolism ; Central Nervous System - physiopathology ; Central Nervous System Agents - therapeutic use ; Humans ; Major depressive disorder ; Mental Disorders - drug therapy ; Mental Disorders - metabolism ; Mental Disorders - physiopathology ; Mental Disorders - psychology ; Oxidation-Reduction ; Oxidative Stress - drug effects ; Redox balance ; Schizophrenia</subject><ispartof>Pharmacology &amp; therapeutics (Oxford), 2020-06, Vol.210, p.107520-107520, Article 107520</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-97033cc9a691f2e14e37699b17c24f3effc76fe978d630ea16dde9622cdf3c3c3</citedby><cites>FETCH-LOGICAL-c374t-97033cc9a691f2e14e37699b17c24f3effc76fe978d630ea16dde9622cdf3c3c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0163725820300486$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32165136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rossetti, Andrea Carlo</creatorcontrib><creatorcontrib>Paladini, Maria Serena</creatorcontrib><creatorcontrib>Riva, Marco Andrea</creatorcontrib><creatorcontrib>Molteni, Raffaella</creatorcontrib><title>Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention</title><title>Pharmacology &amp; therapeutics (Oxford)</title><addtitle>Pharmacol Ther</addtitle><description>While neurotransmitter dysfunction represents a key component in mental illnesses, there is now a wide agreement for a central pathophysiological hub that includes hormones, neuroinflammation, redox mechanisms as well as oxidative stress. With respect to oxidation-reduction (redox) mechanisms, preclinical and clinical evidence suggests that an imbalance in the pro/anti-oxidative homeostasis toward the increased production of substances with oxidizing potential may contribute to the etiology and manifestation of different psychiatric disorders. The substantial and continous demand for energy renders the brain highly susceptible to disturbances in its energy supply, especially following exposure to stressful events, which may lead to overproduction of reactive oxygen and nitrogen species under conditions of perturbed antioxidant defenses. This will eventually induce different molecular alterations, including extensive protein and lipid peroxidation, increased blood-brain barrier permeability and neuroinflammation, which may contribute to the changes in brain function and morphology observed in mental illnesses. This view may also reconcile different key concepts for psychiatric disorders, such as the neurodevelopmental origin of these diseases, as well as the vulnerability of selective cellular populations that are critical for specific functional abnormalities. The possibility to pharmacologically modulate the redox system is receiving increasing interest as a novel therapeutic strategy to counteract the detrimental effects of the unbalance in brain oxidative mechanisms. This review will describe the main mechanisms and mediators of the redox system and will examine the alterations of oxidative stress found in animal models of psychiatric disorders as well as in patients suffering from mental illnesses, such as schizophrenia and major depressive disorder. In addition, it will discuss studies that examined the effects of psychotropic drugs, including antipsychotics and antidepressants, on the oxidative balance as well as studies that investigated the effectiveness of a direct modulation of oxidative mechanisms in counteracting the behavioral and functional alterations associated with psychiatric disorders, which supports the promising role of the redox system as a novel therapeutic target for the improved treatment of brain disorders.</description><subject>Animal models</subject><subject>Animals</subject><subject>Antidepressants</subject><subject>Antioxidants - therapeutic use</subject><subject>Antipsychotics</subject><subject>Central Nervous System - drug effects</subject><subject>Central Nervous System - metabolism</subject><subject>Central Nervous System - physiopathology</subject><subject>Central Nervous System Agents - therapeutic use</subject><subject>Humans</subject><subject>Major depressive disorder</subject><subject>Mental Disorders - drug therapy</subject><subject>Mental Disorders - metabolism</subject><subject>Mental Disorders - physiopathology</subject><subject>Mental Disorders - psychology</subject><subject>Oxidation-Reduction</subject><subject>Oxidative Stress - drug effects</subject><subject>Redox balance</subject><subject>Schizophrenia</subject><issn>0163-7258</issn><issn>1879-016X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1vGyEQhlHUKHbT_oWKYy_r8rEGb2-u1bSRLOWSSLkhMgxZrN3FBWw1_z67cdocIw6D0PPODA8hlLMFZ1x92y32rU19aTHZhWBietZLwc7InK90U43M_QcyH4ustFiuZuRjzjvGWF0zcUFmUnC15FLNSXvzNzhbQhyqhO4A0432CK0dQu4zDQPd5ydogy0pAHUhx-Qw5e90TYd4xI4Wmx6xUB8TfVnKQuziYwDbjeGC6YjD1PQTOfe2y_j5tV6Su6uft5vf1fbm1_Vmva1A6rpUjWZSAjRWNdwL5DVKrZrmgWsQtZfoPWjlsdErpyRDy5Vz2CghwHkJ47kkX0999yn-OWAupg8ZsOvsgPGQjZBay5qxJRvR1QmFFHNO6M0-hd6mJ8OZmTybnXnzbCbP5uR5jH55nXJ46NH9D_4TOwI_TgCOfz0GTCZDwAHQhYRQjIvh_SnPpt6Wng</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Rossetti, Andrea Carlo</creator><creator>Paladini, Maria Serena</creator><creator>Riva, Marco Andrea</creator><creator>Molteni, Raffaella</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202006</creationdate><title>Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention</title><author>Rossetti, Andrea Carlo ; Paladini, Maria Serena ; Riva, Marco Andrea ; Molteni, Raffaella</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-97033cc9a691f2e14e37699b17c24f3effc76fe978d630ea16dde9622cdf3c3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animal models</topic><topic>Animals</topic><topic>Antidepressants</topic><topic>Antioxidants - therapeutic use</topic><topic>Antipsychotics</topic><topic>Central Nervous System - drug effects</topic><topic>Central Nervous System - metabolism</topic><topic>Central Nervous System - physiopathology</topic><topic>Central Nervous System Agents - therapeutic use</topic><topic>Humans</topic><topic>Major depressive disorder</topic><topic>Mental Disorders - drug therapy</topic><topic>Mental Disorders - metabolism</topic><topic>Mental Disorders - physiopathology</topic><topic>Mental Disorders - psychology</topic><topic>Oxidation-Reduction</topic><topic>Oxidative Stress - drug effects</topic><topic>Redox balance</topic><topic>Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rossetti, Andrea Carlo</creatorcontrib><creatorcontrib>Paladini, Maria Serena</creatorcontrib><creatorcontrib>Riva, Marco Andrea</creatorcontrib><creatorcontrib>Molteni, Raffaella</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacology &amp; therapeutics (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rossetti, Andrea Carlo</au><au>Paladini, Maria Serena</au><au>Riva, Marco Andrea</au><au>Molteni, Raffaella</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention</atitle><jtitle>Pharmacology &amp; therapeutics (Oxford)</jtitle><addtitle>Pharmacol Ther</addtitle><date>2020-06</date><risdate>2020</risdate><volume>210</volume><spage>107520</spage><epage>107520</epage><pages>107520-107520</pages><artnum>107520</artnum><issn>0163-7258</issn><eissn>1879-016X</eissn><abstract>While neurotransmitter dysfunction represents a key component in mental illnesses, there is now a wide agreement for a central pathophysiological hub that includes hormones, neuroinflammation, redox mechanisms as well as oxidative stress. With respect to oxidation-reduction (redox) mechanisms, preclinical and clinical evidence suggests that an imbalance in the pro/anti-oxidative homeostasis toward the increased production of substances with oxidizing potential may contribute to the etiology and manifestation of different psychiatric disorders. The substantial and continous demand for energy renders the brain highly susceptible to disturbances in its energy supply, especially following exposure to stressful events, which may lead to overproduction of reactive oxygen and nitrogen species under conditions of perturbed antioxidant defenses. This will eventually induce different molecular alterations, including extensive protein and lipid peroxidation, increased blood-brain barrier permeability and neuroinflammation, which may contribute to the changes in brain function and morphology observed in mental illnesses. This view may also reconcile different key concepts for psychiatric disorders, such as the neurodevelopmental origin of these diseases, as well as the vulnerability of selective cellular populations that are critical for specific functional abnormalities. The possibility to pharmacologically modulate the redox system is receiving increasing interest as a novel therapeutic strategy to counteract the detrimental effects of the unbalance in brain oxidative mechanisms. This review will describe the main mechanisms and mediators of the redox system and will examine the alterations of oxidative stress found in animal models of psychiatric disorders as well as in patients suffering from mental illnesses, such as schizophrenia and major depressive disorder. In addition, it will discuss studies that examined the effects of psychotropic drugs, including antipsychotics and antidepressants, on the oxidative balance as well as studies that investigated the effectiveness of a direct modulation of oxidative mechanisms in counteracting the behavioral and functional alterations associated with psychiatric disorders, which supports the promising role of the redox system as a novel therapeutic target for the improved treatment of brain disorders.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>32165136</pmid><doi>10.1016/j.pharmthera.2020.107520</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0163-7258
ispartof Pharmacology & therapeutics (Oxford), 2020-06, Vol.210, p.107520-107520, Article 107520
issn 0163-7258
1879-016X
language eng
recordid cdi_proquest_miscellaneous_2377340050
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animal models
Animals
Antidepressants
Antioxidants - therapeutic use
Antipsychotics
Central Nervous System - drug effects
Central Nervous System - metabolism
Central Nervous System - physiopathology
Central Nervous System Agents - therapeutic use
Humans
Major depressive disorder
Mental Disorders - drug therapy
Mental Disorders - metabolism
Mental Disorders - physiopathology
Mental Disorders - psychology
Oxidation-Reduction
Oxidative Stress - drug effects
Redox balance
Schizophrenia
title Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T09%3A32%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxidation-reduction%20mechanisms%20in%20psychiatric%20disorders:%20A%20novel%20target%20for%20pharmacological%20intervention&rft.jtitle=Pharmacology%20&%20therapeutics%20(Oxford)&rft.au=Rossetti,%20Andrea%20Carlo&rft.date=2020-06&rft.volume=210&rft.spage=107520&rft.epage=107520&rft.pages=107520-107520&rft.artnum=107520&rft.issn=0163-7258&rft.eissn=1879-016X&rft_id=info:doi/10.1016/j.pharmthera.2020.107520&rft_dat=%3Cproquest_cross%3E2377340050%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2377340050&rft_id=info:pmid/32165136&rft_els_id=S0163725820300486&rfr_iscdi=true